CGTN
8.3.2021 20:08:11 CET | Business Wire | Press release
China is mulling improving the electoral system of the Hong Kong Special Administrative Region (HKSAR) – but critics say it's a plan to eliminate opposition forces in the city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005793/en/
Why are improvements imperative?
When explaining the draft decision on improving the electoral system of the HKSAR to lawmakers, Wang Chen, vice chairman of the National People's Congress (NPC) Standing Committee, said the move is to prevent anti-China, destabilizing forces from seizing power, citing the months-long riots in 2019.
"To remedy the situation, it is important to take necessary steps to improve the electoral system and remove existing institutional deficiencies and risks to ensure the administration of Hong Kong by Hong Kong people with patriots as the main body," Wang said.
Alex Fan, founding president of the International Youth Legal Exchange Federation in Hong Kong, told CGTN that "allowing non-patriots or even people endangering national security to participate in the election will put the 'One Country, Two Systems' in peril."
What can be improved?
According to the draft decision, the focus of the improvements will be on the reform and greater empowerment of the city's Election Committee.
"Hong Kong's chief executive will continue to be elected by the Election Committee. The committee will also elect a relatively large share of Legislative Council (LegCo) members and directly participate in the nomination of all LegCo candidates," Wang said, adding that the revisions to be made may be limited to Annex I and Annex II to the Basic Law, without revising the main body of the Basic Law.
How will it be carried out?
A two-step approach, namely, "decision plus amendment," has been put forward. The NPC, China's top legislature, first makes a decision on improving the electoral system of the HKSAR and authorizes its Standing Committee to amend. Then the NPC Standing Committee amends the Annex I and Annex II to the Basic Law of the HKSAR.
After the amendment at the state level is completed, the HKSAR will amend relevant local laws accordingly.
In consideration of the complexity of Hong Kong's election-related local laws, experts believe the process will take some time but will be completed before elections in Hong Kong in the second half of the year.
What would the improvements mean?
Li Huan, an associate research fellow at the Hong Kong and Macao Research Center, rejected concerns that the non-establishment camp in Hong Kong would have no room to participate in politics after the amendment, saying the decision "does not aim to serve the pro-establishment camp or to restrict the non-establishment camp."
"It depends on how one understands the non-establishment camp. People from the non-establishment camp are not necessarily unpatriotic or those who don't love Hong Kong," Li told CGTN.
This echoed the words of Xia Baolong, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and head of the Hong Kong and Macao Affairs Office of the State Council, who has said the emphasis on "patriots governing Hong Kong" is not meant to erase all differences.
Liu Zhaojia, the vice chairman of the National Hong Kong and Macao Research Association, added: "Pro-establishment candidates can also rest easy. They must put in real efforts to solve Hong Kong's social and livelihood problems in order to gain a better political future."
The Liaison Office of the HKSAR voiced support for improving the electoral system, stating "it is the only way for Hong Kong society to end political disputes, refocus on development and protect the long-term prosperity and stability."
The HKSAR delegation to the Two Sessions said the proposed improvements would not make any change to "One Country, Two Systems," but would strengthen the principle, as well as put an end to the political chaos in Hong Kong and allow local society to focus on economic development, people's livelihood and the SAR's integration into the overall development of the country.
No one cares more about Hong Kong's democracy and continued prosperity and stability than the Central Government of China, Chinese State Councilor and Foreign Minister Wang Yi stated on Sunday, adding that Hong Kong's shift from chaos to stability serves the interests of all parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
